Literature DB >> 33637133

Early Covid-19 vaccination rollout: a commentary from England.

Fiona Sim1.   

Abstract

Early, rapid, nationally orchestrated vaccine rollout has been a feature in the response to the global coronavirus pandemic in Israel and the UK, two countries with long established, universal socialised health care systems. Although there are many differences between England and Israel, the factors influencing the early days of the rollout merit exploration and learning that could be of benefit to other countries as they grapple to plan their own Covid-19 vaccine programmes. This commentary considers aspects of the rollout in both countries, in response to the article by Rosen and colleagues that identified contributing and facilitating factors in Israel. Whilst vaccine procurement and authorisation has been on a UK basis, and many features of rollout have been similar throughout the UK, the details provided pertain to England.

Entities:  

Keywords:  Covid-19; Rollout; Vaccination

Mesh:

Substances:

Year:  2021        PMID: 33637133      PMCID: PMC7907783          DOI: 10.1186/s13584-021-00451-3

Source DB:  PubMed          Journal:  Isr J Health Policy Res        ISSN: 2045-4015


  3 in total

1.  Covid-19: Order to reschedule and delay second vaccine dose is "totally unfair," says BMA.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-12-31

2.  Between individualism and social solidarity in vaccination policy: the case of the 2013 OPV campaign in Israel.

Authors:  Hagai Boas; Anat Rosenthal; Nadav Davidovitch
Journal:  Isr J Health Policy Res       Date:  2016-12-21

3.  Israel's rapid rollout of vaccinations for COVID-19.

Authors:  Bruce Rosen; Ruth Waitzberg; Avi Israeli
Journal:  Isr J Health Policy Res       Date:  2021-01-26
  3 in total
  8 in total

Review 1.  An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.

Authors:  Cielo García-Montero; Oscar Fraile-Martínez; Coral Bravo; Diego Torres-Carranza; Lara Sanchez-Trujillo; Ana M Gómez-Lahoz; Luis G Guijarro; Natalio García-Honduvilla; Angel Asúnsolo; Julia Bujan; Jorge Monserrat; Encarnación Serrano; Melchor Álvarez-Mon; Juan A De León-Luis; Miguel A Álvarez-Mon; Miguel A Ortega
Journal:  Vaccines (Basel)       Date:  2021-04-27

2.  Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel's COVID-19 vaccination program.

Authors:  Bruce Rosen; Ruth Waitzberg; Avi Israeli; Michael Hartal; Nadav Davidovitch
Journal:  Isr J Health Policy Res       Date:  2021-08-02

3.  Sharing reflections and expressing appreciation upon completing a decade as co-editor of the IJHPR.

Authors:  Bruce Rosen
Journal:  Isr J Health Policy Res       Date:  2021-12-15

4.  Critical policies disparity of the first and second waves of COVID-19 in the United Kingdom.

Authors:  Manfei Yang; Leiyu Shi; Haiqian Chen; Xiaohan Wang; Jun Jiao; Meiheng Liu; Junyan Yang; Gang Sun
Journal:  Int J Equity Health       Date:  2022-08-22

5.  Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?

Authors:  Giuseppe Lippi; Brandon Michael Henry; Mario Plebani
Journal:  Diagnostics (Basel)       Date:  2021-05-25

Review 6.  Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature.

Authors:  Vincenza Gianfredi; Flavia Pennisi; Alessandra Lume; Giovanni Emanuele Ricciardi; Massimo Minerva; Matteo Riccò; Anna Odone; Carlo Signorelli
Journal:  Vaccines (Basel)       Date:  2021-06-01

Review 7.  Potential metal-related strategies for prevention and treatment of COVID-19.

Authors:  Ya-Qiong Ni; Hui-Hui Zeng; Xian-Wen Song; Jun Zheng; Hui-Qiong Wu; Chun-Tai Liu; Yi Zhang
Journal:  Rare Metals       Date:  2022-01-17       Impact factor: 6.318

8.  Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.

Authors:  Denis Sauré; Miguel O'Ryan; Juan Pablo Torres; Marcela Zuniga; Emilio Santelices; Leonardo J Basso
Journal:  Lancet Infect Dis       Date:  2021-09-09       Impact factor: 25.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.